Cynata Completes Key Phase 2 Milestone in aGvHD Trial, Data Due June
Cynata Therapeutics has completed the 100-day primary evaluation period for its Phase 2 trial of CYP-001 in acute graft versus host disease, with results expected in June 2026. This milestone marks a critical step for the biotech’s lead cell therapy candidate in a condition with few effective treatments.
- 100-day primary evaluation period completed for all 65 trial participants
- Phase 2 trial of CYP-001 targets acute graft versus host disease (aGvHD)
- Trial is randomised, double-blind, placebo-controlled across Australia, USA, Europe
- Primary endpoint: Overall Response Rate at Day 28; results expected June 2026
- Other clinical programs progressing, including Phase 3 osteoarthritis and Phase 1/2 kidney transplant trials
A Significant Clinical Milestone
Cynata Therapeutics Limited (ASX:CYP) has announced the completion of the 100-day primary evaluation period for the last participant in its pivotal Phase 2 clinical trial of CYP-001, a stem cell therapy candidate for acute graft versus host disease (aGvHD). This milestone signals the end of the primary data collection phase for all 65 enrolled patients across multiple continents, including Australia, the United States, and Europe.
The trial, which is randomised, double-blind, and placebo-controlled, compares the standard steroid treatment plus CYP-001 against steroids plus placebo. The primary endpoint focuses on the Overall Response Rate at Day 28, a key measure of the therapy’s effectiveness in managing this often fatal complication of bone marrow transplantation.
Context on aGvHD and CYP-001’s Promise
aGvHD occurs when donor immune cells attack the recipient’s tissues following transplant, affecting up to half of all patients receiving donor grafts. Current first-line steroid treatments fail in about 50% of cases, with survival rates historically below 20% for steroid-resistant patients. CYP-001, derived from Cynata’s proprietary Cymerus™ induced pluripotent stem cell technology, aims to modulate the immune response and improve outcomes.
Earlier Phase 1 data showed encouraging results, with 87% of steroid-resistant patients responding overall, 53% achieving complete response, and 60% surviving at least two years post-treatment. The therapy has also been granted Orphan Drug Designation by the US FDA, underscoring its potential in a rare and serious condition.
Broader Clinical Pipeline Progress
Alongside the aGvHD program, Cynata’s other clinical trials remain on track. The Phase 3 SCUlpTOR trial of CYP-004 for osteoarthritis of the knee, involving 321 patients, is expected to report results in the second quarter of 2026. Meanwhile, the Phase 1/2 NEREID trial assessing CYP-001 in kidney transplant patients is advancing following a positive safety review.
CEO Dr Kilian Kelly highlighted the significance of reaching the last patient’s last visit in the aGvHD trial, emphasising the company’s commitment to addressing a condition with limited treatment options. The upcoming data readout in June will be closely watched by investors and the medical community alike.
Bottom Line?
June’s data release will be a pivotal moment for Cynata’s lead therapy and its future in aGvHD treatment.
Questions in the middle?
- Will CYP-001 demonstrate a statistically significant improvement in Overall Response Rate at Day 28?
- How will safety and adverse event profiles compare between CYP-001 and placebo groups?
- What impact might the Phase 2 results have on regulatory and commercial prospects for CYP-001?
